Amarin Corp Plc (AMRN)

[Pharmacydude]

Kiwi
I don’t see any scientific reason to expect Vascepa to be less effective against the Delta variant or any other variant. If the Delta variant has a mutation in the antibody binding site that reduces the antibodies ability to attach (and flag the immune system to attack) then the virus is allowed to reproduce and spread.

If Vascepa has direct antiviral properties it is likely because it causes membrane destabilization which kills the virus. This would not be affected by a change in the antibody binding site.

If Vascepa works by restoring balance to the immune system and prevents an overreaction of the inflammatory portion of the immune response this again would not be altered because the virus has an altered binding site.

Because neither of the two above mentioned mechanisms of action rely on anything specific to the Covid SARS-Cov-2 virus itself this is why Vascepa would likely be effective in the flu sepsis and many other immune dysregulation conditions.

As for your earlier question, I have no idea which variant is the primary infection in Argentina